Advertiser / Brand
Johnson & Johnson vs STADA
Structured technology and market comparison · 2026
Direct Feature Comparison
Johnson & Johnson · vs · STADALarge public healthcare manufacturer and commercial products company.
Pharmaceutical group selling generics, specialty medicines and consumer healthcare.
Analyze all overlapping signals and tech stacks for Johnson & Johnson and STADA
Compare mutual enterprise clients, monetization models, live market signals, and partner networks directly in the interactive Knowledge Graph.
Comparison Analysis
What is the main difference between Johnson & Johnson and STADA?
When comparing Johnson & Johnson and STADA, both platforms operate within the Advertiser / Brand ecosystem. Johnson & Johnson is positioned as Large public healthcare manufacturer and commercial products company, whereas STADA focuses on Pharmaceutical group selling generics, specialty medicines and consumer healthcare. Decision-makers evaluate both solutions when orchestrating their commercial monetization and technology stack.
What are the top alternatives to Johnson & Johnson and STADA?
When evaluating Johnson & Johnson and STADA, enterprise buyers also consider other platforms in Advertiser / Brand. You can discover the full competitive landscape and evaluate other alternatives by viewing their respective footprint profiles on Polaris7.
How do the corporate scale, structure, and headquarters of Johnson & Johnson and STADA compare?
Johnson & Johnson is headquartered in United States (founded in 1887) with >5,000 employees. STADA is based in Germany (founding year unrecorded) with >5,000 employees. Complete ownership, subsidiary trees, and corporate affiliations are documented across Polaris7.
Market Signals
Recent Market Signals & Activity: Johnson & Johnson vs STADA
Documented market movements, strategic partnerships, product releases, and regulatory developments mapped across Polaris7.
Johnson & Johnson
Recent Signals
- ·SEC APIfinancials
10-Q Financial Filing Analysis for Johnson & Johnson (2026-10-21)
Johnson & Johnson reported fiscal Q3 2026 sales to customers of $25.40 billion, up 5.9% year-over-year (6.0% operational growth), driven by double-digit growth in Oncology and steady demand in MedTech, which offset biosimilar erosion from STELARA. However, consolidated net earnings collapsed to $210 million (diluted EPS of $0.09) from $5.15 billion in Q3 2025. This sharp profitability decline was primarily caused by a $5.5 billion pre-tax accrual recorded in Other (income) expense, net for a proposed comprehensive settlement of the talc ovarian cancer litigation, alongside a $1.0 billion in-process R&D charge from the Firefly Bio acquisition and ongoing Orthopaedics separation costs.
- Worldwide sales reached $25.40 billion in Q3 2026 (+5.9% YoY) and $74.77 billion for the first nine months (+7.4% YoY), supported by gains in DARZALEX ($4.24 billion in Q3) and TREMFYA ($2.40 billion in Q3).
- Net earnings plummeted to $210 million in Q3 2026 due to a $5.5 billion litigation charge to resolve ovarian talc claims and a $1.0 billion acquired IPR&D charge for Firefly Bio, Inc.
- Total present value of reserves for talc-related legal matters reached approximately $9.0 billion as of September 27, 2026, while the planned separation of the Orthopaedics business remains on track for mid-2027.
- ·Johnson & Johnson
Johnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy
Revolutionary IL-23R targeted oral peptide delivers sustained skin clearance and a favorable safety profile in patients with psoriasis affecting sensitive, highly visible areas of the body. 60% of patients with scalp psoriasis and 89% with genital psoriasis achieved site-specific complete skin clearance at Week 112.
- ·Johnson & Johnson
A behind-the-scenes look at how Johnson & Johnson manufactures and delivers CAR-T cell therapy for multiple myeloma
Johnson & Johnson published a behind-the-scenes feature on September 25, 2026, highlighting how the company manufactures and delivers CAR-T cell therapy for multiple myeloma. The article focuses on the complexity of producing and distributing this personalized cancer treatment. No specific clinical data, product names, or commercial terms are disclosed in the provided text.
- Johnson & Johnson published a behind-the-scenes feature on September 25, 2026.
- The article focuses on Johnson & Johnson's CAR-T cell therapy manufacturing and delivery for multiple myeloma.
- The provided article text does not reveal specific product names, trial results, or financial terms.
STADA
Recent Signals
No recent market signals documented for STADA in the current tracking window.
Compare their exact ecosystem overlaps.
Explore all deep relationships in Polaris7. Discover exactly which mutual clients, integrated technologies, and overlapping partners Johnson & Johnson and STADA share across the market ecosystem.
Unlock full capability matrix, client overlaps & technology stacks